Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 6,362 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William Sibold sold 6,362 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the sale, the chief executive officer owned 202,967 shares in the company, valued at approximately $108,707,095.53. This trade represents a 3.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

William John Sibold also recently made the following trade(s):

• On Friday, September 11th, William Sibold sold 5,221 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $542.39, for a total transaction of $2,831,818.19.

Madrigal Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:MDGL opened at $534.49 on Friday. The firm has a market capitalization of $12.35 billion, a PE ratio of -41.47 and a beta of -0.98. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20. Madrigal Pharmaceuticals, Inc. has a 52-week low of $393.61 and a 52-week high of $615.00. The firm has a fifty day moving average of $530.99 and a 200 day moving average of $507.63.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. The business had revenue of $364.25 million for the quarter, compared to the consensus estimate of $352.13 million. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%.The company’s revenue for the quarter was up 71.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.90) earnings per share. As a group, research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 EPS for the current fiscal year.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd bought a new position in shares of Madrigal Pharmaceuticals in the second quarter worth approximately $29,000. Global Retirement Partners LLC bought a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $34,000. Kemnay Advisory Services Inc. purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $39,000. Quarry LP bought a new stake in Madrigal Pharmaceuticals in the 3rd quarter worth $39,000. Finally, Accent Capital Management LLC grew its holdings in Madrigal Pharmaceuticals by 64.9% in the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 37 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MDGL. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, June 24th. UBS Group restated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 31st. Wells Fargo & Company started coverage on shares of Madrigal Pharmaceuticals in a research note on Monday, July 27th. They issued an “overweight” rating and a $685.00 price objective for the company. Finally, Barclays reduced their target price on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Fifteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $699.64.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic diseases, particularly nonalcoholic steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH).

The company’s lead product is Rezdiffra (resmetirom), an oral, thyroid hormone receptor beta agonist designed to target underlying liver disease. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH and moderate to advanced liver fibrosis.